Evidence map›Paper›PMID 39543471›Full record

ArticleBMC infectious diseases2024

Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Southwestern Oromia, Ethiopia: ten-year retrospective analysis.

Zegeye Bonsa, Mulualem Tadesse, Eba Bekele, Gari Abeba, Endashaw Solomon, Mohammed Husen, Getu Balay, Wakjira Kebede, Gemeda Abebe

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zegeye BonsaMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia. bonsazegeye2015@gmail.com.
Mulualem TadesseMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.
Eba BekeleMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.
Gari AbebaMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.
Endashaw SolomonMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.
Mohammed HusenShanan Gibe General Hospital, Jimma, Oromia, Ethiopia.
Getu BalayMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.
Wakjira KebedeMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.
Gemeda AbebeMycobacteriology Research Center, Jimma University, P. O. Box 378, Jimma, Oromia, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB) requires the use of second-line anti-TB drugs, which are less effective and more toxic. This study assessed treatment outcomes and factors associated with unfavorable treatment outcomes among RR/MDR-TB patients in Southwestern Oromia, Ethiopia.

methodsA multicenter retrospective study was conducted on 226 RR/MDR-TB patients (six extrapulmonary and 220 pulmonary) treated under a national TB program between 2013 and 2022 at five treatment facilities in Southwestern Oromia, Ethiopia. RR/MDR-TB patient data, such as sociodemographic, clinical, and laboratory results and treatment outcomes, were collected from the RR/MDR-TB registry using a standard data extraction form between April and June 2023. Logistic regression analysis was used to explore the associations between risk factors and unfavorable treatment outcomes.

resultsAmong 220 pulmonary RR/MDR-TB patients, 181 (82.3%) achieved favorable treatment outcomes (161 cured and 20 treatment completed). However, 39 (17.7%) patients had unfavorable treatment outcomes (12 were lost to follow-up, seven experienced treatment failure, and 20 died). Of the six extrapulmonary RR/MDR-TB patients, five (83.3%) had favorable treatment outcomes, and one (16.7%) was lost to follow-up. Pulmonary RR/MDR-TB patients with HIV infection (AOR = 4.85, 95% CI: 1.90 to 12.39), history of previous TB treatment (AOR = 3.09, 95% CI: 1.21 to 7.86), and low baseline BMI (AOR = 2.86, 95% CI: 1.06 to 7.72) had increased risk of unfavorable treatment outcomes.

conclusionAlthough the majority of RR/MDR-TB patients have favorable treatment outcomes, a significant proportion of patients still experienced unfavorable outcomes. Patients with HIV infection, history of previous TB treatment, and low baseline BMI require special attention to improve pulmonary RR/MDR-TB treatment outcomes. Future studies with larger sample sizes are required to evaluate treatment outcomes and associated factors among patients with extrapulmonary RR/MDR-TB.

Indexed as

Antitubercular AgentsTuberculosis, Multidrug-ResistantAdolescentAdultEthiopiaFemaleHIV InfectionsHumansMaleMiddle AgedMycobacterium tuberculosisRetrospective StudiesRifampinRisk FactorsTreatment OutcomeYoung AdultAntitubercular AgentsRifampinDrug resistanceTreatment outcomesTuberculosisUnfavorable outcomes

Identifiers

PMID39543471
PMCPMC11566186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.